Spots Global Cancer Trial Database for Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
Official Title: A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma
Study ID: NCT04649073
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tokai University Hospital, Isehara-shi, , Japan
National Hospital Organization Okayama Medical Center, Okayama-shi, , Japan
Tohoku University Hospital, Sendai-shi, , Japan
Japanese Red Cross Medical Center, Shibuya-ku, , Japan
Osaka University Hospital, Suita-shi, , Japan
Contact Details
Name: Nobuhito Sanada
Affiliation: Otsuka Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
